Cargando…
Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults
CD101 IV is a novel echinocandin with distinctive pharmacokinetic properties that is being developed as a once-weekly treatment for candidemia and invasive candidiasis. CD101 has potent in vitro activity and in vivo efficacy against a broad range of Candida and Aspergillus species. The primary objec...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278714/ https://www.ncbi.nlm.nih.gov/pubmed/27919901 http://dx.doi.org/10.1128/AAC.01627-16 |